The use of nonviral gene therapy vectors has been hampered by low level of transfection efficiency and lack of sustained gene expression. Episomal self-replicating systems may overcome these hurdles through their large packaging capacity, stability and reduced toxicity. This article reviews three classes of episomal molecules that have been tested with possible therapeutic genes: (1) self-replicating circular vectors, containing the Epstein-Barr virus (EBV) elements oriP and EBNA1; (2) small circular vectors containing scaffold/matrix attachment regions (S/MARs) as cis-acting elements to maintain the episomal status of the vector; (3) chromosomal vectors, based on the functional elements of the natural chromosomes. The studies reported validate the use of episomal vectors to obtain stable and prolonged gene expression, although reveal some limitations that necessitate additional work.
There is a current need for alternatives to nonviral vectors Nonviral vectors have attracted a large amount of attention in recent years because of lack of specific immune responses, endogenous virus recombination or oncogenic effects, as can occur with viral gene transfer agents. 1 On the other hand, nonviral vectors have some disadvantages, including low efficiency and the lack of a sustained gene expression profile. Improvement in both delivery methods and the modular design of the DNA itself has brought about large degrees of enhancement in the efficiency and temporal control of nonviral vectors, 2 but much work is still to be done.
Prolonged transgene expression can be achieved by including constitutive human or tissue-specific promoters 3, 4 or by stable chromosomal integration of plasmid DNA by the use of transposon 5, 6 or phage integrase. [7] [8] [9] However, these systems may arise concerns due to insertional mutagenesis and positional effects. Extrachromosomal self-replicating systems offer multiple advantages, including large packaging capacity allowing the presence of genomic regulatory elements and stability without integration. Episomal-maintained vectors can be categorized into three general groups: (1) self-replicating viral-based vectors, (2) scaffold/matrix-attached regions (S/MAR)-containing vectors and (3) chromosome-based vectors.
Prolonged gene expression is achieved with Epstein-Barr virus (EBV)/human vectors
Self-replicating viral-based vectors are capable of longterm episomal persistence in mammalian cells. These vectors contain component derived from either EBV or bovine papilloma virus, 10 but most progress for gene therapy applications has been made with the former. EBV is a human herpesvirus that is capable of maintaining its genome extrachromosomally in dividing mammalian cells. Maintenance is accomplished by the viral latent origin of replication oriP, and the EBV nuclear antigen 1, EBNA1, which act together to replicate the viral genome and retain it in the nucleus ( Figure 1a) . 15 Inclusion of these EBV sequences on conventional plasmid vectors allows them to replicate and be retained in dividing cells. 16 Other studies have pointed out that genomic sequences are effective in preventing silencing of gene expression, as it occurs with viral promoter/enhancers. The transfection efficiency of a plasmid vector containing the full genomic human a 1 -antitrypsin (AAT) gene with its natural promoter was studied by hydrodynamic tailvein injection, a procedure known to give efficient (approximately 40%) transfection of liver cells in vivo. This plasmid mediated long-term (44 months) therapeutic levels of hAAT protein in mouse plasma, whereas cDNA constructs exhibited different biphasic kinetics, with the hAAT protein levels dropping approximately two orders of magnitude from day 1 to day 30. 17 The positive features of EBV components (episomal replication and retention) and of genomic sequences (tissue specificity, proper regulation and prevention of silencing of gene expression) were combined in fruitful constructs that provided therapeutic levels of proteins, such as AAT and factor IX (FIX), in mice. 16 Recently, by using a construct containing an hFIX minigene (comprised of apoE gene hepatic locus control region, the hepatocyte-specific hAAT promoter, part of the FIX intron A and the 3 0 -untranslated region) (Figure 1b ). Sclimenti et al have shown that, by adding the EBV EBNA1 gene and its family of repeats binding sites to this construct, a single dose of vector generated normal (45 mg/ml) levels of hFIX throughout the 8 months duration of the experiment. 13 In contrast, the construct containing only the hFIX minigene provided 10-to 100-fold lower hFIX levels, which steadily declined and fell after 4 months below the threshold of detection. Notwithstanding, the EBV components were also able to stimulate gene expression from the 33-kb hFIX full genomic construct by at least an order of magnitude, such that hFIX levels of B1 mg/ml were observed over a 81-day time course. The greater stability of gene expression of EBV vectors could be, however, only in part explained by higher retention in cells. Indeed, vector DNA content in liver cells was lowest for the plasmid that gave the best expression, that is, the EBV/FIX minigene.
14 Thus, it is likely that EBV sequences provide not only nuclear retention, and thus sustained expression, but also enhance transgene expression. Indeed, EBNA1-oriP interaction has been documented to facilitate nuclear transfer of episomal DNA and binding of plasmid DNA to the nuclear matrix, and to have transcriptional enhancer activity. 15, 16 One obvious advantage of hybrid EBV/human vectors could be their use in delivery of large human DNA fragments (complete with replication origins). A 'secondgeneration' noninfectious and nontransforming EBVbased vector, carrying the entire 185-kb human b-globin gene locus (including the locus control region), was shown to be maintained as an episome for a period of 3 months, even in the absence of selection.
14 The episome retention rate was greater than 93% over 90 cell doublings. Moreover, a correctly spliced human b-globin transcript was found in all late-passage cell cultures in the absence of selective pressure.
The majority of studies involving EBV-based episomal vectors has focused on cancer (suicide gene or immunogene therapy) and diseases originating from hematopoietic progenitor cells, 15 that is in mitotically active systems. On the other hand, an advantage of using EBV vectors over conventional plasmids (in terms of high level and persistence of expression) has also been shown in organs with a low proliferative index, that is, liver, lung and heart. 15, 11, 12 These interesting features presented by the EBV-based vectors may be ascribed to multiple functions of EBNA1, which binds oriP in a sequence-specific manner facilitating nuclear transfer of the plasmid and binding of the plasmid to the nuclear matrix (acting as an S/MAR, see below).
The EBV is a causative agent of infectious mononucleosis as well as various malignancies in human, so it raises some concerns about safety. Interestingly, more Figure 1 Schematic representation of EBV-based plasmid vectors. In the more simplistic version (a), the EBNA1 gene and oríP element are included in a conventional plasmid bearing a cDNA (transgene) whose expression is driven by a constitutive or viral promoter/enhancer (Promoter). 11, 12 In the hybrid EBV/human construct (b), the EBNA1 and oriP were cloned in a plasmid containing an hFIX minigene, comprising locus control region, intron and 3 0 untranslated region, or full genomic sequences.
13,14
Episomally maintained self-replicating systems M Conese et al than 90% of the worldwide adult population is latently infected with EBV. In these individuals, a primary silent infection is established early in childhood, and the virus persistently resides in pharyngeal epithelium and B cells throughout life without causing any serious disease. The EBNA1-expressing cells are not eliminated by cytotoxic T lymphocytes because EBNA1 escapes from MHC class I presentation. 18 However, since EBV is an oncogenic virus, the potential oncogenicity of the EBV-derived vectors has to be examined. It has been shown that other EBV gene products are required for transformation of resting B cells in vitro, while EBNA1 per se is not able to transform human cells. However, it was demonstrated that EBNA1 transgenic mice succumb to monoclonal B-cell lymphoma by acting on cellular responses involved in the growth and apoptosis of B cells. 19 To exclude the possibility that EBV-based vectors could trigger tumor development in human, it has to intensively investigate the possible oncogenicity in vivo of the vectors using nonhuman primates and other large animals.
Yeast and bacterial artifical chromosomes (YACs and BACs) can be retrofitted into large EBV-based episomes EBV viral elements (oriP and EBNA1) can be used as an alternative to the centromere to provide stable maintenance and segregation of large DNA molecules in mammalian cells. Therefore, constructs were assembled to insert the oriP/EBNA1 module into YAC and BAC clones. Modification of the YACs have been obtained by yeast homologous recombination using constructs containing the oriP/EBNA1 cassette and regions of homology to the YAC arms. The resulting molecules are large circular episomes. More recently, retrofitting vectors have been assembled to insert oriP/ EBNA1 into BACs by using Cre recombinase. 20 The procedure consists in the cotransfection of loxP-BAC-containing clones with the retrofitting plasmid, containing the oriP/EBNA1 cassette, one loxP site and selectable markers, and the Cre-expression plasmid. The latter ensures transient expression of the Cre protein which mediates site-specific recombination and insertion of the retrofitting fragment into the BAC vector. By this method BACs containing human DNA fragments of 70, 130 and 150 kb in size have been converted to oriP/ EBNA1 episomes. The resulting molecules showed the expected structure in most of the clones analyzed. Following this strategy, the 320 kb YAC-yCFTR, containing the intact human CFTR gene with its long-range controlling elements, was circularized and introduced into mouse LA-9 cells, which do not express endogenous CFTR gene as well as into mouse CMT-93 cells, which express the endogenous CFTR. In both experiments, the construct was stably maintained as episomal element and the human CFTR gene was shown to be expressed although at different levels among the cell clones analyzed, demonstrating that YAC/oriP/ EBNA1 episomes enable stable and persistent expression of the cloned genes. It is worth noting that the persistence of these molecules depends on the continuous presence of the viral factor EBNA1 which may be unfavorable for gene therapy (see section above for discussion on this topic).
S/MARs act as cis-acting elements for sustained gene expression in vivo
In higher eukaryotes, DNA replication occurs in tight association with the nuclear matrix, where binding of the replication origin to the nuclear matrix must precede the onset of S phase. Most characterized mammalian origins of replication are associated with S/MARs. Moreover, S/ MARs are known to provide insulation effects between transcription units. Thus, S/MAR sequences have been exploited to guarantee episomal replication and stability. A vector was constructed which contained the origin of replication of the simian virus 40 genome (SV40 ori) linked to an S/MAR sequence isolated from the human b-interferon gene (Figure 2a ). This vector, pEPI-1, replicates episomally in the absence of large T antigen at a copy number of 10 in CHO cells and is stably retained in these cells in the absence of selection for over 100 generations. 23 There is a specific interaction of this vector with the nuclear matrix and the chromosome scaffold and pEPI-1 has a pronounced affinity to the matrix protein SAF-A (scaffold attachment factor-A). 21 Although pEPI-1 is not strictly a self-replicating system, this interaction enables a 'piggy-back' mechanism by which it is passed efficiently to daughter cells. Further work showed that the expression of transgenes encoded by the vector is not subjected to silencing, even in the absence of selection, and that this construct also 21 (a) or the minigene 22 (b). The minigene contains the hFIX cDNA with a portion of the first intron from the hFIX gene driven by the human a 1 -antitrypsin promoter and liver-specific enhancers.
Episomally maintained self-replicating systems M Conese et al functions in other cell lines, including human and primary cells. 23 Administration of pEPI-1 to the lung via intravenous injection did not result in prolonged transgene (luciferase) expression or DNA persistence when compared to a conventional plasmid (A Bragonzi and M Conese, unpublished results). Since transgene expression in these experiments was driven by the CMV promoter, these results could indicate that even these S/MAR-containing small circular vectors are prone to promoter attenuation. Thus, constitutive or tissue-specific promoters have to be combined with these sequences to achieve long-term expression in vivo. This was also suggested by the recent work of Ehrhardt et al. 22 An S/MAR sequence derived from the chicken lysozyme locus (ChMAR) was added as a cis-acting element flanking an hFIX expression cassette that contained a portion of the first intron of the hFIX gene and the 3 0 untranslated region driven by the AAT promoter, apolipoprotein E enhancer and hepatocyte control region (Figure 2b ). After transfection into the liver, the vector containing the ChMAR resulted in higher level of expression 1 day after injection, and 1 year postinjection animals receiving this vector expressed five times higher levels of hFIX (up to 8 mg/ml) compared to the vector without S/MAR. Interestingly, real-time PCR on liver genomic DNA showed that the differences in transgene expression levels were not caused by the loss of vector genomes within the hepatocytes, suggesting an effect of S/MARs either on vector replication or on transcription.
Chromosome-based vectors are considered the ideal vehicles to introduce exogenous genes into new hosts
The development of chromosomal vectors, which is based on the construction of DNA molecules that approximate normal chromosomes, was envisioned ever since the construction of the first artificial chromosomes, the YACs and their successful utilization as cloning vectors. These molecules offer some important advantages with respect to conventional viral and nonviral vectors since they replicate autonomously at one-two copies per cell and have an unlimited cloning capacity allowing the insertion of entire genes (exons and introns) with the proper regulatory elements. Since artificial chromosomes are independent molecules, they should be free of possible adverse events such as insertional mutagenesis and positional effects. However, simple and efficient techniques to transfer these molecules into cells still have to be developed. In this section, we will review state of the art of technology taking into consideration both the methods used to assemble artificial chromosomes and the molecules that have been constructed with therapeutic genes.
Artificial chromosomes can be obtained by in vitro chromosome assembly (bottom up) and by reducing the size of natural chromosome (top down)
Artificial chromosomes can be constructed following two approaches: (1) the 'bottom-up' approach that consists of the assembly of structural chromosomal elements, namely a centromere, origin of replication and telomeres, in a unique functional molecule ( Figure 3a and b) ; 24 (2) the 'top-down' approach based on the size reduction of a natural chromosome by means of different pruning procedures such as telomere fragmentation or induction of double-strand breaks by irradiation (Figure 4a  and b) . 25 Multiple rounds of chromosome fragmentation have been used to derive smaller and smaller derivatives from natural chromosomes. We will refer to the molecules obtained by the first procedure as de novo Figure 3 De novo chromosome formation can be obtained by using a DNA mixture containing centromeric DNA (a-satellite), telomeric fragments (optional) and random genomic (optional) transfected into human cultured cells (a). Alternative strategies were developed which make use of centromeric yeast and bacterial vectors (b).
Episomally maintained self-replicating systems M Conese et al chromosomes and the ones obtained by means of chromosome truncation as mini-chromosomes (MCs). MCs can be also isolated directly from patients with chromosomal rearrangements. The construction of de novo chromosomes is currently limited because the sequence requirements for centromere function and for mammalian origins of replication have not been precisely established. However, in reality, the origin does not pose a problem since in the presence of centromeric DNA, or DNA elements with nuclear retention signals (oriP/EBNA1, S/MARs), it has been shown that large pieces of DNA (few tens of kb) are generally competent for replication. The human centromere is a very big structure composed of a few megabases of repetitive DNA, the a satellite DNA, to which many different proteins, both constitutive and cell-cycle regulated, converge to form the kinetochore. This is a trilaminar structure responsible for attaching the chromososmes to the spindle microtubules. The organization of the a satellite DNA changes from chromosome to chromosome and consists of multimers of higherorder repeats of the basic 171 bp monomer. The monomers within each higher-order repeat are 65-90% identical to each other, whereas the higher-order repeats are highly homogeneous. Among the various higherorder repeats arrays tested for centromere function in cultured cells, only a subset was shown to be active, and their activity correlated with the presence of the binding site for the centromeric protein CenpB (CenpB-box). In fact, by using homogeneous synthetic repeated arrays of the basic 171 bp alphoid monomer and non-alphoid DNA with and without CenpB-box, it was demonstrated that only alphoid DNA with CenpB-box, but not other sequences, are required for chromosome formation. 26 A variety of constructs containing the most efficient alphoid arrays, isolated from chromosome 21 and 17, have been assembled in YAC, PAC (P1 artificial chromosome) and BAC vectors, in order to evaluate their potential to induce chromosome formation in the fibroblast cell line HT1080 (Figure 3b) . 27, 28 These experiments demonstrated that de novo chromosomes formation occurred in a fraction (30-40% under best conditions) of the isolated clones, whereas in the remaining clones integration of alphoid DNA into the host chromosomes was observed. 26, 28 The latter event is particularly unfavorable since it may cause activation of a new centromere at ectopic position. 29 The molecules obtained from the de novo and top-down approach share some important similarities. They are mitotically stable and maintained at low copy numbers and are 1-10 Mb in size and mainly composed of alphoid DNA confirming the primary role of the centromeric DNA in chromosome maintenance. Beyond these similarities, de novo chromosomes, with the exception of few linear examples, are suspected to be circular, even when produced with linear constructs. The fact that they are larger than the input DNA is probably due to a multimerization process that produces an undefined structure. Conversely, the MCs maintain the structure of the natural chromosomes from which they derive, are linear and have functional telomeres. Moreover, it has recently been shown that de novo chromosomes exhibit a higher frequency of segregation errors (1.6-9.7% per chromosome per generation) with respect to natural chromosomes (0.33-1.1% per chromosome per generation). Two types of errors have been mainly observed: nondisjunction and anaphase lag; the frequency of these defects are statistically different between natural and artificial chromosomes suggesting that the latter responds differently to the mechanisms causing segregation errors. 30 Although MCs have not been tested for segregation errors, analysis of their mitotic stability revealed a decreased stability of small MCs with respect to larger molecules of the same origin, suggesting the requirements of an optimal size for full chromosome function.
Artificial chromosomes enable sustained expression and activity of potential therapeutic genes
De novo chromosomes and MCs have both been used as vectors for delivering therapeutic genes into cultured cells, and in all cases the expression and the activity of the therapeutic genes have been demonstrated, supporting the idea that active genes can be cloned into chromosomal vectors. De novo chromosomes have been assembled with human genes cloned into the same construct as the centromeric DNA, or by cotransfection of two constructs, the centromeric PAC or BAC vector and the transgene cloned into a BAC. 31 The human genes hypoxanthine guanine phosphoribosyltransferase (HPRT1) and the guanosine triphosphate cyclohydrolase (GCH1) were used in these constructs and their activity was assessed in the host cells. De novo chromosomes containing these genes were assembled in HPRTdeficient human fibrosarcoma cells (HT1080) and selected for complementation of the HPRT À phenotype. HPRT expression was demonstrated in a time course experiment off selection from the starting to 60 day points. Similarly, de novo chromosomes containing GCH1 were shown to express active GCH1 in response to IFN-g in a pattern similar to endogenous expression. 31 The validity of chromosome therapy in vivo was demonstrated by Marynen and co-workers who used an MC designated SAC (small accessory chromosome) to produce chimeric trans-chromosomal mice expressing the human tissue factor gene (F3) present in the SAC. More recently, they improved this chromosomal vector (CV) by assembling a neo-loxP-3'HPRT-minigene cassette to retrofit CV with large DNA fragments Episomally maintained self-replicating systems M Conese et al (PAC-sized). By this procedure, the authors assembled an MC with the human CSN2 and STATH genes that was shown to be germline transmitted and mitotically stable. Expression studies demonstrated that although the F3 gene was actively expressed, the two additional human genes were inactive probably due to the absence of proper control elements. 32 Mitotic and meiotic transmission of MCs in mice was investigated by Brown and coworkers who demonstrated that a 4.5 Mb MC containing mouse minor and major satellite DNA (called ST1) is mitotically stable in both germline and somatic lineages, and that both female and male mice transmitted the MC to the offspring although with a different efficiency (50 and 20% of the offspring, respectively). 33 More recently, the production of trans-chromosomal calves with MCs containing the human immunoglobulin gene further supports the feasibility of chromosome therapy in vivo. 34 Another MC derived from a natural chromosome has been used as a vector for human genes. This molecule (MC1, 5.5 Mb), derived from human chromosome 1 by g-irradiation of a monosomatic CHO hybrid cell line, was used as a cloning and expression vector for the human genes IL-2 (MC1-IL2) and CFTR (MC1-CFTR). MC1-CFTR was assembled with the 300 kb YAC vector containing the entire CFTR gene (27 exons) plus 70 kb upstream exon 1 that reasonably includes the entire sets of regulatory elements. It was constructed in CHO cells containing MC1 by yeast protoplast fusion. 35 The CFTR activity was assayed in the three selected clones that showed the presence of the MC with the expected structure by means of molecular and functional assays. Northern and Western analysis showed the presence of the transcript and the protein at similar level to that of the positive controls (human cells expressing the CFTR gene). Immunofluorescence analysis demonstrated that CFTRp is present in most of the MC1-CFTR-containing cells, but it is correctly transported to plasma membrane only in 3-4% of the cell population; this is most probably due to the unfavorable cellular background. Consistently with this results, CFTR channel activity was demonstrated by chloride efflux experiments. Presently no data are available on the expression of CFTR in CFTRdeficient cells. MC1 may be considered the first chromosomal vector described and, similarly to the canonical vectors, it can be engineered with different genes without altering its structural and functional features. The assembly of MC1-CFTR is of particular relevance since it may represent a valid alternative to the gene therapy protocols developed for cystic fibrosis patients. Although such protocols demonstrated proofof-principle for the effective gene transfer in those patients, they suffered from important limitations in sustained long-term gene expression. 3 
Prospects
Episomally maintained self-replicating vectors can host transgenes of up to several hundred kb in size. This feature gives extrachromosomal vectors the ability to carry full genomic sequences, including endogenous promoters, enhancers and matrix-attachment regions. The improvement in the duration of gene expression in vivo in the liver obtained by hybrid human/EBV vectors has to be validated and extended to other organs. The development of physical delivery methods administration, like electrotransfer and magnetofection, 2,36 will be instrumental to target genomic vectors to many different cell types in vivo. Moreover, their versatility makes them an attractive gene therapy system for treating not only inherited diseases, but also cancer, cardiovascular disease and to vaccinate against a variety of acquired diseases.
An S/MAR element might be one of the components constituting either genomic or hybrid human/viral vectors. Recent work has shown that not only S/MAR sequences are important for episomal maintenance but are endowed with 'transcriptional augmentation' and 'bordering element/insulator' functions and may prevent the methylation-dependent inactivation process. In this respect, S/MARs may develop into extremely valuable tools, which guarantee the long-term expression of any associated transcription unit.
The work carried out to date on the development of chromosomal vectors to be used in gene therapy revealed not only the feasibility of this naïve idea but also the necessity to improve the vectors and to work intensely on the methods to transfer these molecules into the affected cells. Optimization of vectors is particularly necessary for constructs used to generate de novo chromosomes since several steps must be precisely identified in choosing the sequence required for chromosome formation, the structure of the resulting molecules, the effects of the procedure on the host genome, and finally whether a specific cellular background is required. The answers to these questions will open up a new frontier for gene therapy, based on the treatment of the defective tissue and/or organs with the appropriate DNA mixture giving rise to a new chromosome containing the desired gene directly into the affected organs. Alternatively, therapeutic chromosomes can be engineered into host cell lines, purified and transferred into the patients. The use of MCs also requires the development of efficient transfection protocols. Chromosome transfer techniques have not been improved in the last few years, and all experiments reported in the literature have made use of cell fusion in vitro. This method is very inefficient and requires a selection procedure to isolate the rare clones that have acquired the MCs. We speculate that in the near future researchers will pay particular attention to the development of techniques for purification of chromosomes of small size and to the discovery of proper transfection reagents. That this will be possible is suggested by the finding that MCs of quite large size (60 Mb) can be transferred to cultured cells by using commercial transfection agents. Among the 20 commercially available agents tested, the best results were obtained with Superfect (cationic dendrimer) and Lipofectamine 2000 (cationic lipid). More recently, a study carried out with BACs 70-130 kb in size confirmed that Lipofectamine 2000 was the best transfection reagents both in vitro and in vivo, in terms of efficiency and integrity of the transfected DNA. 37 
